Watch

Peptides in 30 seconds.

Tap one, turn the sound on, swipe for the next. Same videos as our Instagram, X and YouTube, minus the hype. Every FDA status is dated, so you know it’s current.

0:29FDA Status Check

Six peptides got a yes from FDA advisers. What it actually means.

0:30Myth or Fact?

Thirty years of BPC-157 research. Here’s what it shows.

0:32Next Approval Watch

CagriSema: two peptides, one weekly shot, one FDA decision to watch.

0:32FDA explained

The FDA changed the rules on 12 peptides. Most posts got it wrong.

0:27True story

This peptide was once FDA-approved. So what happened?

0:30Next-gen GLP-1

The next Ozempic? Retatrutide’s real timeline.

0:34Myth check

Is BPC-157 “legal now”? Not exactly.

0:34Peptides 101

Your body already makes its own Ozempic.

0:46The peptide wave

Why is everyone suddenly talking about peptides?

Transcripts

Every video, word for word, with a link to the sourced article behind it.

FDA Status Check · 29s · checked Oct 7, 2026Six peptides got a yes from FDA advisers. What it actually means.

Six peptides just got a yes from FDA advisers. Here’s what it actually means.

In July 2026, an FDA advisory committee recommended BPC-157, TB-500 and four others.

For the 503A list, the one that lets licensed pharmacies compound them, with a prescription.

A vote is advice. The next step is an FDA rule, and as of October 7, it hasn’t been proposed yet.

Vote done. Rule next. That’s the moment to watch.

Myth or Fact? · 30s · checked Oct 7, 2026Thirty years of BPC-157 research. Here’s what it shows.

Thirty years of BPC-157 research. Here’s what it actually shows.

A 2025 review counted about three dozen studies since 1993.

Most in rats and mice, with consistent signals across independent labs: tendon, ligament, gut lining.

And human research has started: a 2025 safety pilot in two healthy adults reported no serious side effects.

Next up: randomized human trials. That’s what turns promising into proven.

Next Approval Watch · 32s · checked Oct 7, 2026CagriSema: two peptides, one weekly shot, one FDA decision to watch.

Two peptides, one weekly shot, and an FDA decision expected before 2027.

It’s called CagriSema: semaglutide, the peptide in Wegovy, plus cagrilintide, a version of the hormone amylin.

Novo Nordisk filed for FDA approval in December 2025.

In its main trial of over three thousand adults, average weight loss was 20 percent, versus 3 on placebo. Nausea and other stomach side effects were common.

It’s still investigational. The decision is the moment to watch.

FDA explained · 32s · checked Oct 6, 2026The FDA changed the rules on 12 peptides. Most posts got it wrong.

The FDA changed the rules on twelve peptides this year, and most posts got it wrong.

There are three different lists: a safety-concern list, a pharmacy list, and full FDA approval.

In April, twelve peptides came off the safety-concern list. That includes BPC-157 and TB-500.

In July, FDA advisers backed six of seven for the pharmacy list. But there’s still no final rule.

And none of the twelve is FDA-approved. Less restricted doesn’t mean proven.

True story · 27s · checked Oct 6, 2026This peptide was once FDA-approved. So what happened?

This peptide was once an FDA-approved drug. So what happened?

It’s called sermorelin. It was sold as Geref, for kids with growth hormone deficiency, until the maker stopped selling it.

In 2013, the FDA confirmed it wasn’t pulled for safety or effectiveness reasons.

That history is why licensed pharmacies still prepare it today, with a prescription.

The honest part: proof for adult wellness use is still thin.

Next-gen GLP-1 · 30s · checked Oct 6, 2026The next Ozempic? Retatrutide’s real timeline.

Everyone’s calling it the next Ozempic. It’s called retatrutide.

In its biggest trial, people on the top dose lost twenty-five percent of their body weight on average.

The secret? It hits three hormone targets at once. Ozempic hits just one.

The catch: it’s not approved yet. Lilly plans to file with the FDA in early 2027.

So a decision likely lands in late 2027. And those research vials online? Not the medicine from the trials.

Peptides 101 · 34s · checked Oct 6, 2026Your body already makes its own Ozempic.

Your body already makes its own version of Ozempic.

It’s a gut hormone called GLP-1. Every time you eat, your gut releases it, and it tells your brain you’re full.

But here’s the catch: your natural GLP-1 is gone in about two minutes.

Ozempic is a lab-made copy of that same peptide, built to last about a week. That’s why it’s a once-a-week shot.

Wegovy is the same molecule. Zepbound goes further and copies two gut hormones at once.

And unlike most peptides you see online, these passed huge trials and FDA approval.

The peptide wave · 46s · checked Oct 6, 2026Why is everyone suddenly talking about peptides?

Why is everyone suddenly talking about peptides?

Reason one: the biggest drugs of the decade, Ozempic, Wegovy and Zepbound, are all peptides.

Reason two: in April the FDA took twelve peptides off its restricted list, and in July its advisers backed six of seven.

Reason three: the next generation is close. Retatrutide hit twenty five percent average weight loss in a major trial, and CagriSema has an FDA decision expected this quarter.

The part most posts skip: coming off a restricted list is not the same as FDA approval.